National Pharmaceutical Pricing Authority said major Pharma companies have announced voluntary price cuts for Remdesivir Injections after Centre’s intervention to ensure it’s affordable availability. Cadila Healthcare’s Remdac will now cost 899 rupees instead of Rupees 2800.
Syngene International’s RemWin will now cost 2 thousand 450 rupees instead of 3 thousand 950 rupees. Dr Reddy’s Redyx will be available at 2 thousand 700 rupees instead of 5 thousand 400 rupees. Cipla’s Cipremi will cost 3 thousand rupees instead of 4 thousand rupees. Mylan Pharmaceutical’s Desrem will be available at 3 thousand 400 rupees instead of 4 thousand 800 rupees. Jubilant Generic’s Jubi-R will now cost 3 thousand 400 rupees instead of 4 thousand 700 rupees. Hetero Healthcare’s Covifor will be available at 3 thousand 490 rupees instead of 5 thousand 400 rupees.
Remdesivir injection is used to treat coronavirus disease 2019 (COVID-19 infection) caused by the SARS-CoV-2 virus in hospitalized adults and children 12 years of age and older who weigh at least 88 pounds (40 kg). Remdesivir is in a class of medications called antivirals. It works by stopping the virus from spreading in the body. (Ref: Mediline Plus)